OROS Methylphenidate Long-Term Study in ADHD
Once-daily osmotic controlled-release (OROS) methylphenidate (Concerta) in the treatment of 407 children, aged 6-13 years, with ADHD who were known MPH responders, was evaluated in a 24-month multicenter, open-label, nonrandomized study, and reported from the Massachusetts General Hospital, Boston.
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Pediatric Neurology Briefs Publishers,
2003-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_bcb4f0f566b94c20a137c7ce174c3828 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a J Gordon Millichap |e author |
| 245 | 0 | 0 | |a OROS Methylphenidate Long-Term Study in ADHD |
| 260 | |b Pediatric Neurology Briefs Publishers, |c 2003-05-01T00:00:00Z. | ||
| 500 | |a 1043-3155 | ||
| 500 | |a 2166-6482 | ||
| 500 | |a 10.15844/pedneurbriefs-17-5-9 | ||
| 520 | |a Once-daily osmotic controlled-release (OROS) methylphenidate (Concerta) in the treatment of 407 children, aged 6-13 years, with ADHD who were known MPH responders, was evaluated in a 24-month multicenter, open-label, nonrandomized study, and reported from the Massachusetts General Hospital, Boston. | ||
| 546 | |a EN | ||
| 690 | |a osmotic controlled-release | ||
| 690 | |a insomnia | ||
| 690 | |a methylphenidate | ||
| 690 | |a Pediatrics | ||
| 690 | |a RJ1-570 | ||
| 690 | |a Neurology. Diseases of the nervous system | ||
| 690 | |a RC346-429 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pediatric Neurology Briefs, Vol 17, Iss 5, Pp 40-40 (2003) | |
| 787 | 0 | |n https://www.pediatricneurologybriefs.com/articles/1517 | |
| 787 | 0 | |n https://doaj.org/toc/1043-3155 | |
| 787 | 0 | |n https://doaj.org/toc/2166-6482 | |
| 856 | 4 | 1 | |u https://doaj.org/article/bcb4f0f566b94c20a137c7ce174c3828 |z Connect to this object online. |